Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262
Brief Summary: This phase III clinical trial studies two different dose schedules of paclitaxel to see how well they work in combination with carboplatin with or without bevacizumab in treating patients with stage II, III or IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is a type of drug called a monoclonal antibody and blocks tumor growth by stopping the growth of blood vessels that tumors need to grow. It is not yet known whether giving paclitaxel with combination chemotherapy once every three weeks is more effective than giving paclitaxel once a week in treating patients with ovarian, primary peritoneal, or fallopian tube cancer.


Options:
A: Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tamoxifen citrate; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
B: Arm Label: A:Paclitaxel + Carboplatin every 3 weeks; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel + Carboplatin every 3 weeks | Arm Label: B:Carboplatin monotherapy every 3 weeks; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin monotherapy every 3 weeks | Arm Label: C:Weekly Paclitaxel and Carboplatin; Type: EXPERIMENTAL; Interventions: Drug: Weekly Paclitaxel and Carboplatin | Intervention Type: DRUG; Name: Paclitaxel + Carboplatin every 3 weeks; Assigned to Arm(s): A:Paclitaxel + Carboplatin every 3 weeks | Intervention Type: DRUG; Name: Carboplatin monotherapy every 3 weeks; Assigned to Arm(s): B:Carboplatin monotherapy every 3 weeks | Intervention Type: DRUG; Name: Weekly Paclitaxel and Carboplatin; Assigned to Arm(s): C:Weekly Paclitaxel and Carboplatin
C: Arm Label: Participants receiving Niraparib; Type: EXPERIMENTAL; Interventions: Drug: Niraparib | Arm Label: Participants receiving Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Niraparib; Assigned to Arm(s): Participants receiving Niraparib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Participants receiving Placebo
D: Arm Label: Arm I (adjuvant chemotherapy suboptimally debulked); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Procedure: Computed Tomography, Drug: Paclitaxel, Procedure: Therapeutic Conventional Surgery | Arm Label: Arm II (neoadjuvant chemotherapy); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Procedure: Computed Tomography, Drug: Paclitaxel, Procedure: Therapeutic Conventional Surgery | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy)

Answer: D